Albireo Pharma, Inc. - Common Stock (NQ:ALBO)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Mar 2, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Albireo Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

81 Biggest Movers From Yesterday ↗

May 18, 2022

Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results.

Via Benzinga

48 Stocks Moving In Tuesday's Mid-Day Session ↗

May 17, 2022

Gainers Okyo Pharma Ltd. ADR (NASDAQ: OKYO) gained 30% to $5.20 as the company priced its IPO at $4 per ADS.

Via Benzinga

Mid-Morning Market Update: Markets Open Higher; Walmart Earnings Miss Estimates ↗

May 17, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.

Via Benzinga

Albireo Pharma: Q1 Earnings Insights ↗

May 16, 2022

Albireo Pharma (NASDAQ:ALBO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Albireo Pharma missed estimated...

Via Benzinga

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Albireo Pharma's Earnings Outlook ↗

May 13, 2022

Albireo Pharma (NASDAQ:ALBO) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Albireo Pharma...

Via Benzinga

Albireo Pharma Earnings Perspective: Return On Capital Employed ↗

March 03, 2022

Benzinga Pro data, Albireo Pharma (NASDAQ:ALBO) reported Q4 sales of $32.52 million. Earnings fell to a loss of $10.96 million, resulting in a 119.2% decrease from last quarter....

Via Benzinga

Recap: Albireo Pharma Q4 Earnings ↗

March 01, 2022

Albireo Pharma (NASDAQ:ALBO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

80 Biggest Movers From Yesterday ↗

March 02, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...

Via Benzinga

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 ↗

December 27, 2021

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...

Via Benzinga

Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ALBO earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Albireo Pharma Sells Bylvay-Associated PRV For $105M ↗

September 07, 2021

Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus...

Via Benzinga

Looking into Albireo Pharma's Return on Capital Employed ↗

August 27, 2021

After pulling data from Benzinga Pro it seems like during Q2, Albireo Pharma (NASDAQ:ALBO) posted sales of $2.43 million. Earnings were up 16.96%, but Albireo Pharma still...

Via Benzinga

Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript ↗

August 07, 2021

ALBO earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates ↗

August 02, 2021

The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting...

Via Talk Markets

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US ↗

July 21, 2021

Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat...

Via Benzinga

Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease ↗

July 19, 2021

The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic...

Via Benzinga

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗

July 18, 2021

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,...

Via Talk Markets

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗

July 18, 2021

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...

Via Benzinga

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗

July 01, 2021

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...

Via Benzinga

Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study ↗

June 21, 2021

Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of...

Via Benzinga

Albireo's Bylvay Wins Positive Opinion from EMA For Rare Pediatric Liver Disease ↗

May 21, 2021

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc...

Via Benzinga

Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Call Transcript ↗

May 07, 2021

ALBO earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.